NASDAQ: AMIXAutonomix Medical Inc Stock
*Your capital is at risk. Other fees apply.
$1.42-0.15 (-9.55%)
Updated Jul 1, 2025
AMIX Price
$1.42
Fair Value Price
N/A
Market Cap
$3.95M
52 Week Low
$1.14
52 Week High
$42.40
P/E
-0.22x
P/B
0.49x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.41M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$8M
Beta
0.56
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AMIX Overview
Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AMIX's potential to beat the market
- AMIX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
AMIX
RankedUnranked of 105
RankedUnranked of 105
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.52 | A | |
| $30.60 | A | |
| $21.80 | A |
Be the first to know about important AMIX news, forecast changes, insider trades & much more!
AMIX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AMIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AMIX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AMIX is good value based on its book value relative to its share price (0.49x), compared to the US Medical Devices industry average (4.12x)
P/B vs Industry Valuation
AMIX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AMIX due diligence checks available for Premium users.
Valuation
AMIX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
36.47x
Market
31.77x
AMIX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.49x
Industry
4.12x
AMIX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AMIX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
AMIX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$9.8M
Liabilities
$1.7M
Debt to equity
0.21
AMIX's short-term assets ($9.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMIX's short-term assets ($9.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.5M
Investing
-$4.0k
Financing
-$174.0k
AMIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AMIX vs Medical Device Stocks
Autonomix Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.